Skip to main content

Table 1 Characteristics of study population and by outcomes of interests; SARS-CoV-2 infections, hospitalisation, intensive care unit (ICU) admission, and death in Norway, 15 July–30 November 2021

From: Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

  

Total study population

SARS-CoV-2 infection

Hospitalisation

ICU admission

COVID-19 deaths

n

%

n

%

n

%

n

%

n

%

All

-

4,301,995

-

74,371

-

1429

-

290

-

331

-

Age groups

18–24 years

457,238

10.6

11,499

15.5

24

1.7

1

0.3

0

0.0

 

25–34 years

747,249

17.4

16,013

21.5

113

7.9

16

5.5

2

0.6

 

35–44 years

705,460

16.4

17,131

23.0

190

13.3

40

13.8

2

0.6

 

45–54 years

735,420

17.1

14,050

18.9

206

14.4

46

15.9

6

1.8

 

55–64 years

653,259

15.2

7440

10.0

202

14.1

63

21.7

22

6.6

 

65–74 years

540,898

12.6

4604

6.2

214

15.0

52

17.9

38

11.5

 

75–84 years

335,628

7.8

2557

3.4

301

21.1

59

20.3

103

31.1

 

≥ 85 years

126,843

2.9

1077

1.4

179

12.5

13

4.5

158

47.7

Sex

Male

2,160,307

50.2

37,098

49.9

791

55.4

196

67.6

185

55.9

 

Female

2,141,688

49.8

37,273

50.1

638

44.6

94

32.4

146

44.1

Underlying conditions

No risk group

3,401,381

79.1

62,802

84.4

711

49.8

129

44.5

78

23.6

 

Medium risk

788,954

18.3

10,247

13.8

524

36.7

115

39.7

180

54.4

 

High risk

111,660

2.6

1322

1.8

194

13.6

46

15.9

73

22.1

Country of birth

Norway

3202,876

74.5

46,501

62.5

791

55.4

170

58.6

247

74.6

 

Outside Norway

802,615

18.7

25,579

34.4

506

35.4

103

35.5

34

10.3

 

Unknown

296,504

6.9

2291

3.1

132

9.2

17

5.9

50

15.1

Crowding

Yes

336,777

7.8

11,953

16.1

175

12.2

29

10.0

7

2.1

 

No

3,728,263

86.7

57,206

76.9

1154

80.8

238

82.1

299

90.3

 

Unknown

236,955

5.5

5212

7.0

100

7.0

23

7.9

25

7.6